Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

The clinical utility of MALDI-TOF MS in multiple myeloma

Jialu Wu, Xia Ge, Zhiyao Zhang, Yufang Liang, Wen Gao, Wenming Chen

Blood (2025) 146 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2025-2230

Published: 2025

Journal Articles

Efficacy and safety of aponermin combined with immunomodulators in relapsed/refractory multiple myeloma

Xiujuan Huang, Yanping Ma, Zhenyu Li, Juan Li, Yuzhang Liu, Yaomei Wang, Chao Song, Xiaoqi Qin, Wenming Chen, Yi Wang

Blood (2025) 146 (Supplement 1): 7571.

https://doi.org/10.1182/blood-2025-7571

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Min Yang, Yang Liang, Guorong Wang, Baijun Fang, Luqun Wang, Songfu Jiang, Yafei Wang, Heng Mei, Wei Yang, Yanjuan He, Wei Wang, Haichao Zhang, Houguo Wang, Jie Jin, Wenming Chen

Blood (2025) 146 (Supplement 1): 5822.

https://doi.org/10.1182/blood-2025-5822

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal

Blood (2025) 146 (Supplement 1): 102.

https://doi.org/10.1182/blood-2025-102

Published: 2025

Journal Articles

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

Qiling Bu, Yiwen Jiang, Jingjing Deng, Ping Wang, Zhiyao Zhang, Guangzhong Yang, Ying Tian, Wen Gao, Aijun Liu, Leng Yun, Yin Wu, Wenming Chen, Honghu Zhu

Blood (2025) 146 (Supplement 1): 7564.

https://doi.org/10.1182/blood-2025-7564

Published: 2025

Journal Articles

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Yingying Huo, Haixiao Zhang, Yebo Peng, Ting Shi, Ya-Lan Zhou, Chuanying Geng, Wenjing Li, Wen Gao, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 769.

https://doi.org/10.1182/blood-2025-769

Published: 2025

Journal Articles

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Wenjing Li, Yin WU, Chuanying Geng, Aijun Liu, Lefu Huang, Leng Yun, Yanru Zhang, Ying Tian, jing jia, Menghan Liu, Huijuan Wang, Guangzhong Yang, Hong-Hu Zhu, Wenming Chen, Wen Gao

Blood (2025) 146 (Supplement 1): 7590.

https://doi.org/10.1182/blood-2025-7590

Published: 2025

Journal Articles

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma

Xiaozhe Li, Chengcheng Fu, Chunrui Li, Song Jin, Di Wang, Huixing Zhou, Jingjing Shang, Guangzhong Yang, Wenming Chen, Juan Li

Blood (2025) 146 (Supplement 1): 7588.

https://doi.org/10.1182/blood-2025-7588

Published: 2025

Journal Articles

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Menghan Liu, Xiaoqi Qin, Weiwei Tian, Yuechen Zhang, Yanru Zhang, Lefu Huang, Wenjing Li, Jingrong Wang, Yanping Ma, Liping Su, Yan Yan, Aijun Liao, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2025-2280

Published: 2025

Journal Articles

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

Gang An, Wenming Chen, Wen Gao, Ting Yang, Lijie Xing, Kaihong Xu, Yan Zhang, Tong Xu, Min Wei, Feng Li, Guojin Wu, Jinying Ning, Lugui Qiu

Blood (2025) 146 (Supplement 1): 2274.

https://doi.org/10.1182/blood-2025-2274

Published: 2025

Journal Articles

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Huixing Zhou, Chunrui Li, Baijun Fang, Lingzhi Yan, Aijun Liu, Peiling Zhang, Yang Liu, Xiaoqi Qin, Huanxin Zhang, Wei Zhou, Hong-Hu Zhu, Leng Yun, Yin WU, Yi Wang, Wenming Chen, Guangzhong Yang

Blood (2025) 146 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2025-2271

Published: 2025

Journal Articles

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Huanxin Zhang, Yi Wang, Chengcheng Fu, Yanli Feng, Yang Liu, Jing Wang, Chunrui Li, Wenming Chen, Zhenyu Li

Blood (2025) 146 (Supplement 1): 2270.

https://doi.org/10.1182/blood-2025-2270

Published: 2025

Journal Articles

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma

Xiaozhe Li, Baijun Fang, Di Wang, Yuzhang Liu, Yanping Ma, Peiling Zhang, Aijun Liu, Wenming Chen, Juan Li

Blood (2025) 146 (Supplement 1): 7580.

https://doi.org/10.1182/blood-2025-7580

Published: 2025

Journal Articles

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Lefu Huang, Yuechen Zhang, Huijuan Wang, Wenjing Li, Yanru Zhang, Menghan Liu, Ying Tian, Zunmin Zhu, Hong-Hu Zhu, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 7576.

https://doi.org/10.1182/blood-2025-7576

Published: 2025

Journal Articles

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Blood (2025) 146 (Supplement 1): 7546.

https://doi.org/10.1182/blood-2025-7546

Published: 2025

Journal Articles

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Menghan Liu, Wen Gao, Wenrong Huang, Xinan Cen, Yuan Jian, Huixing Zhou, jing jia, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2025-5766

Published: 2025

Journal Articles

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Blood (2025) 146 (Supplement 1): 843.

https://doi.org/10.1182/blood-2025-843

Published: 2025

Journal Articles

Immunoglobulin Light Chain Renal Amyloidosis Patients with t(11;14) Have Much More Possibility to be Present As Nephrotic Syndrome

Menghan Liu, Chuanying Geng, Wen Gao, Wenming Chen, Guangzhong Yang

Blood (2024) 144 (Supplement 1): 6876.

https://doi.org/10.1182/blood-2024-202383

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The clinical utility of MALDI-TOF MS in multiple myeloma

Efficacy and safety of aponermin combined with immunomodulators in relapsed/refractory multiple myeloma

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Immunoglobulin Light Chain Renal Amyloidosis Patients with t(11;14) Have Much More Possibility to be Present As Nephrotic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only